Pergolide in the treatment of patients with early and advanced Parkinson's disease

Clinical Neuropharmacology

Volumn 25, Issue 1, 2002, Pages 1-10

  Bonuccelli, Ubaldo ^a   Colzi, Anna ^a   Del Dotto, Paolo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Dopamine agonists; Parkinson's disease; Pergolide

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CABERGOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

ADJUVANT THERAPY; ANOREXIA; CARDIOTOXICITY; CLINICAL TRIAL; DYSKINESIA; ERYTHROMELALGIA; FIBROSIS; HUMAN; HYPOTENSION; LEUKOPENIA; LONG TERM CARE; MONOTHERAPY; NEUROTOXICITY; PARKINSON DISEASE; PLEURA EFFUSION; PRIORITY JOURNAL; REVIEW; SOMNOLENCE;

ANTIPARKINSON AGENTS; BROMOCRIPTINE; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE; PERGOLIDE; RANDOMIZED CONTROLLED TRIALS;

EID: 0036180215     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200201000-00001     Document Type: Review

References (61)

1. The role of dopamine agonists in early Parkinson's disease
2. Pergolide mesylate therapy in Parkinson's disease: Report of a 3-month trial in 20 patients
3. Pergolide in late-stage Parkinson's disease
4. Clinical pharmacology of dopamine agonists in Parkinson's disease
5. Dopamine agonists: Their role in the treatment of Parkinson's disease
6. Interaction of pergolide with central dopaminergic receptors
7. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2, D3 receptors
8. Physiologic disposition of pergolide
9. Pergolide: A review of its pharmacologic properties and therapeutic potential in Parkinson's disease
10. Pergolide in the treatment of Parkinson's disease
11. A review of the efficacy of the dopamine agonists pergolide and bromocriptine in the treatment of Parkinson's disease
12. Pergolide for levodopa-induced motor complications in PD
13. Pergolide versus bromocriptine for levodopa-induced motor complications in PD
14. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients
15. Pergolide monotherapy in the treatment of early PD. A randomised, controlled study
16. Long-term efficacy of pergolide monotherapy in early-stage Parkinson's disease. One-year interim analysis of a 3-year double-blind randomized study versus levodopa
17. Improving the quality of reporting of randomized trials. The CONSORT statement
18. The safety of pergolide monotherapy in early-stage Parkinson's disease. One-year interim analysis of a 3-year double-blind, randomized study of pergolide versus levodopa
19. Treatment of advanced Parkinson's disease with pergolide
20. Pergolide mesylate and idiopathic Parkinson's disease
21. Pergolide therapy in Parkinson's disease: A double-blind, placebo-controlled study
22. Pergolide in the management of advanced Parkinson's disease
23. Double-blind trial of pergolide for Parkinson's disease
24. Parallel double-blind study of pergolide in Parkinson's disease
25. Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease
26. Treatment of Parkinson's disease with pergolide: A double-blind study
27. A multicenter double-blind, placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease
28. Comparison of pergolide and bromocriptine therapy in parkinsonism
29. Pergolide in the treatment of Parkinson's disease
30. Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study
31. The levodopa dosesparing capacity of pergolide compared with that of bromocriptine in an open-label crossover study
32. Pergolide mesylate: Four years experience in Parkinson's disease
33. Long-term study of pergolide in Parkinson's disease
34. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias
35. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa
36. High-dose treatment of Parkinson's disease with pergolide
37. Cardiac effects of pergolide
38. Pergolide mesylate: Lack of cardiac toxicity in patients with cardiac disease
39. Double-blind assessment of potential pergolide-induced cardiotoxicity
40. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease
41. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide
42. Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson's disease
43. Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis
44. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide
45. Pergolide-induced dyspnea, bilateral pleural effusion and peripheral edema
46. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole
47. Sleep attacks and Parkinson's disease treatment
48. Sleep attacks (sleep episodes) with pergolide
49. Adjuncts to levodopa therapy. Dopamine agonists
50. Ropinirole for the treatment of early Parkinson's disease
51. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
52. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial
53. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
54. Pramipexole versus levodopa as initial treatment for Parkinson's disease: A randomized controlled trial
55. Is stimulation old D1 and D2 dopamine receptors important for optimal motor functioning in Parkinson's disease?
56. ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease
57. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys
58. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys
59. Chronic L-Dopa administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus)
60. Dopamine agonists: The treatment for Parkinson's disease in the XXI century?